Biltmore Family Office LLC Buys 2,785 Shares of Johnson & Johnson $JNJ

Biltmore Family Office LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 16.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,132 shares of the company’s stock after purchasing an additional 2,785 shares during the quarter. Biltmore Family Office LLC’s holdings in Johnson & Johnson were worth $3,733,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Greatmark Investment Partners Inc. increased its holdings in Johnson & Johnson by 1.0% in the 3rd quarter. Greatmark Investment Partners Inc. now owns 121,683 shares of the company’s stock worth $22,562,000 after acquiring an additional 1,219 shares during the last quarter. Oxbow Advisors LLC boosted its position in Johnson & Johnson by 1.4% during the third quarter. Oxbow Advisors LLC now owns 45,299 shares of the company’s stock worth $8,399,000 after purchasing an additional 636 shares during the period. BAM Wealth Management LLC bought a new position in Johnson & Johnson during the third quarter worth about $235,000. Trek Financial LLC increased its stake in shares of Johnson & Johnson by 204.1% in the third quarter. Trek Financial LLC now owns 11,529 shares of the company’s stock worth $2,138,000 after purchasing an additional 7,738 shares in the last quarter. Finally, Brueske Advisory Services LLC raised its position in shares of Johnson & Johnson by 5.2% in the third quarter. Brueske Advisory Services LLC now owns 1,873 shares of the company’s stock valued at $347,000 after purchasing an additional 93 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $221.54 on Tuesday. The company has a market capitalization of $533.76 billion, a P/E ratio of 20.05, a P/E/G ratio of 2.14 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $222.17. The company has a fifty day moving average of $208.79 and a 200-day moving average of $189.84.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.46. The business had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.3%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on JNJ shares. Argus raised their price objective on shares of Johnson & Johnson from $210.00 to $240.00 in a report on Friday. Wolfe Research raised their price target on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a report on Monday, January 5th. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. TD Cowen increased their price objective on Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $226.18.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.